ブレオミシン-マイクロバブルコンジュガートによる癌細胞の炭水化物依存的標的化
Jean-Charles Chapuis1, Ryan M Schmaltz, Krystal S Tsosie
1Center for BioEnergetics and Department of Chemistry, Arizona State University, Tempe, Arizona 85287, USA.
Journal of the American Chemical Society
|February 4, 2009
まとめ
微小泡に結合したバイオチニル化ブレオミシンA ((5)) は,正常な細胞ではなく,癌細胞を特異的に標的にし,それに付着する. 顕微鏡で観察できるこの標的型結合は,がん細胞の検出と治療の可能性を示しています.
科学分野:
- バイオメディカルエンジニアリング
- 腫瘍学 腫瘍学
- 細胞生物学 細胞生物学
背景:
- ブレオミシンA(5) は抗がん剤である.
- マイクロバブルは,医療画像と治療で使用されるガスで満たされたマイクロ球です.
- がん細胞への治療薬の標的型投与は,腫瘍学における重要な課題である.
研究 の 目的:
- ブレオミシン由来マイクロバブルを使用して,がん細胞のための標的型配送システムを開発し,評価する.
- 癌細胞系と正常細胞系に結合するブレオミシン-マイクロバブルコンジュガートの特異性を評価する.
主な方法:
- バイオチニル化ブレオミシンA(5) は,ストレプタヴィジン製微小泡に結合された.
- コンジュガートは,培養されたMCF-7細胞および他のがん細胞系に適用されました.
- 結合は観察され,顕微鏡を用いて監視された.
- コントロール実験には,正常な細胞系と微小バブルが,改変されたブレオミシンを含んでいるか,含まれていた.
主要な成果:
- ブレオミシン由来微小泡は,特にMCF-7細胞と他の3つの癌細胞系に固執した.
- 通常の乳がん細胞系 (MCF-10A) や,マッチした非がん細胞系との有意な結合は観察されなかった.
- マイクロバブルにブレオミシンA ((5) または改造されたブレオミシンアナログが存在しないことにより,結合が廃止されました.
結論:
- ブレオミシン由来マイクロバブルは,がん細胞を標的とする高特異性を示しています.
- このコンジュガートは,がん細胞の検出や標的治療の提供のためのツールとして潜在性を示しています.
- ブレオミシンA ((5) の炭水化物分子は,特定の結合相互作用にとって極めて重要です.
関連する概念動画
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
